Tarsus Pharmaceuticals Inc (TARS) — Capital Reinvestment Ratio
Latest as of December 2025:
0.33x
Tarsus Pharmaceuticals Inc (TARS) has a Capital Reinvestment Ratio of 0.33x as of December 2025, meaning it reinvests 0% of its operating cash flow ($19.33 Million) in capital expenditures ($6.36 Million). See TARS free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
0.33x
Capex / Operating Cash Flow
Operating Cash Flow
$19.33 Million
USD
Capital Expenditures
$6.36 Million
USD
Data as of
Dec 2025
Most recent filing
Tarsus Pharmaceuticals Inc Capital Reinvestment Ratio (2021–2021)
This chart tracks Tarsus Pharmaceuticals Inc's Capital Reinvestment Ratio across 1 annual periods.
Annual Capital Reinvestment Ratio for Tarsus Pharmaceuticals Inc (2021–2021)
Year-by-year Capital Reinvestment Ratio for Tarsus Pharmaceuticals Inc from 2021 to 2021. For live market cap and broader valuation context, see Tarsus Pharmaceuticals Inc (TARS) market capitalisation.
| Year | Reinvestment Ratio | Operating CF (USD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2021 | 0.16x | $3.75 Million | $586.00K | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow